Phase 4 Schizoaffective Disorder Clinical Trials

8 recruitingPhase 4

What is a Phase 4 trial?

Phase 4 trials, also called post-marketing studies, are conducted after a treatment has been approved and is available to the public. They monitor long-term effectiveness and safety in a broader population.

Showing 18 of 8 trials

Recruiting
Phase 4

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

SchizophreniaMajor Depressive DisorderBipolar Disorder+2 more
Neurocrine Biosciences50 enrolled19 locationsNCT07105111
Recruiting
Phase 4

Anticholinergic Deprescription in Schizophrenia

SchizophreniaSchizoaffective Disorder
Deepak K. Sarpal, M.D.105 enrolled1 locationNCT06562608
Recruiting
Phase 4

CLOZAPINE Response in Biotype-1

SchizophreniaSchizoaffective DisorderBipolar 1 Disorder
University of Texas Southwestern Medical Center524 enrolled5 locationsNCT04580134
Recruiting
Phase 4

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

SchizophreniaSchizoaffective Disorder
New York State Psychiatric Institute280 enrolled7 locationsNCT05208190
Recruiting
Phase 4

Exercise and Olanzapine-samidorphan

Schizoaffective DisorderSchizophenia DisorderBipolar Disorder I or II+1 more
New York State Psychiatric Institute30 enrolled1 locationNCT06740890
Recruiting
Phase 4

Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia

SchizophreniaSchizoaffective Disorder
Centre for Addiction and Mental Health30 enrolled1 locationNCT02639702
Recruiting
Phase 4

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

SchizophreniaTobacco SmokingParkinsonism+2 more
Corporal Michael J. Crescenz VA Medical Center10 enrolled1 locationNCT03495024
Recruiting
Phase 4

Switching to aripiprazole from other second-generation antipsychotics.

Schizophrenic and schizoaffective disorder
Bristol Meyers Squibb Pharmaceuticals40 enrolled1 locationACTRN12605000516684